dc.contributor.author | Newton, G | |
dc.contributor.author | Wynne, G | |
dc.contributor.author | Keily, J | |
dc.contributor.author | Smyth, D | |
dc.contributor.author | Crew, A | |
dc.coverage.spatial | International | |
dc.date.accessioned | 2020-08-19T10:04:58Z | |
dc.date.issued | 2005-09-27 | |
dc.identifier | https://worldwide.espacenet.com/ | |
dc.identifier | US75234204A | |
dc.identifier | US6949563 (and associated family) | |
dc.identifier.citation | 2005 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/3988 | |
dc.description.abstract | Compounds represented by Formula (I): or a pharmaceutically acceptable salt or N-oxide thereof, wherein R1 is R2 is and R3 is C 0-4 alkyl, are useful in the treatment of cancer. | |
dc.language | eng | |
dc.language.iso | eng | |
dc.subject | Kinase | |
dc.subject | c-Kit | |
dc.subject | KDR | |
dc.title | (2-carboxamido)(3-amino)thiophene compounds | |
dc.type | Patent | |
rioxxterms.licenseref.startdate | 2005-09-27 | |
rioxxterms.type | Other | |
pubs.filed-date | 2004-01-06 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicinal Chemistry 3 | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicinal Chemistry 3 | |
pubs.patent-status | Granted in multiple territories | |
pubs.embargo.terms | Not known | |
icr.researchteam | Medicinal Chemistry 3 | en_US |
dc.contributor.icrauthor | Newton, Gary | |